Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
0
Neutral
8
Bullish
6
Bearish
16
Neutral
8
Bullish
22
Bearish
16
Neutral
0
Bullish
16
Investor Presentation
Q4 FY25
Investor Presentation
Q1 FY25
Investor Presentation
Q4 FY24
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Market Cap
₹ 37 Cr
P/E
80.35
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
37 Cr
Moderate Risk
80.4
43.8
—
1.6
23.77
9.29
Sales CAGR
1Y
26.10%
3Y
20.09%
5Y
7.29%
10Y
25.41%
Profit CAGR
1Y
-4.88%
3Y
—
5Y
4.22%
10Y
52.45%
ROE
TTM
2.04%
3Y
3.63%
5Y
2.87%
10Y
2.09%
ROCE
TTM
2.92%
3Y
3.98%
5Y
3.75%
10Y
3.32%
Performance
MARKET LEADER
Valuation
OVERVALUED
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
MODERATE RISK
Turned 1 L into 4.39 L in last 5 Years